In ovarian cancer, treatment with Azacitidine in the mouse model DNMTi led to an increase in the M1/M2 macrophage ratio as well as recruitment of other immune cells, such as CD8+ T cells and NK cells, while also decreasing MDSC levels [115]. Here, CD8A is linked to ovarian cancer.